Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Balancing commercial and public interests.

Curt D Furberg1, Mark A Hall, Mary Ann Sevick

  • 1Department of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC 27157-1063, USA. cfurberg@wfubmc.edu

Current Controlled Trials in Cardiovascular Medicine
|July 9, 2004
PubMed
Summary

Pharmaceutical companies often delay or spin unfavorable clinical trial results. Expanded government regulations are needed to ensure timely, unbiased drug safety and efficacy information for public health.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In Defense of Using Medical Practice Guidelines Defensively: A Response to Stewart and Peck.

American journal of law & medicine·2026
Same author

COVID-19 testing and vaccination uptake among Spanish-speaking Latine persons: impact of a novel social network intervention.

BMC public health·2026
Same author

Mobile health interventions tailored to immigrant populations with diabetes: an integrative review.

BMC public health·2025
Same author

A Culturally and Linguistically Tailored Intervention to Improve Diabetes-Related Outcomes in Chinese Americans With Type 2 Diabetes: Pilot Randomized Controlled Trial.

JMIR mHealth and uHealth·2025
Same author

Baseline Characteristics of Weight-Loss Success in a Personalized Nutrition Intervention: A Secondary Analysis.

Nutrients·2025
Same author

Exclusion of Elective Care from Hospital Financial Assistance Policies - Arresting a Troubling Development.

The New England journal of medicine·2025

Area of Science:

  • Clinical Trials
  • Pharmaceutical Industry
  • Public Health

Background:

  • A significant number of randomized clinical trials (RCTs) are completed annually, with findings often selectively published.
  • Industry-sponsored trials, in particular, show a trend of rapid reporting for favorable results and delayed or biased reporting for unfavorable outcomes.
  • This selective reporting impacts the dissemination of crucial drug safety and efficacy data.

Discussion:

  • Pharmaceutical firms have social responsibilities to provide complete and unbiased trial information beyond financial obligations.
  • Private markets do not adequately incentivize voluntary disclosure of negative drug safety or inferiority data.
  • Failure to disclose drug inferiority, as seen in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), can harm public interest.

Related Experiment Videos

Key Insights:

  • The selective publication of clinical trial results poses a risk to public health and informed medical decision-making.
  • Non-comparability of drugs due to undisclosed trial data is a critical issue.
  • Current systems for medical information dissemination are insufficient for ensuring full disclosure.

Outlook:

  • Collaboration among stakeholders could improve information dissemination, but full disclosure of unfavorable results remains unlikely without external drivers.
  • Expanded government regulations are proposed as a necessary measure to ensure comprehensive and timely reporting of all clinical trial outcomes.
  • Regulatory intervention is crucial for safeguarding public health interests in the pharmaceutical industry.